Pharmacogenomics Testing Market is anticipated to surpass US$17.9 billion in 2031 at a CAGR of 10.0%

According to a research study published by Knowledge Sourcing Intelligence (KSI), the pharmacogenomics testing market will expand from USD 11.1 billion in 2026 to USD 17.9 billion in 2031 at a CAGR of 10.0% during the forecast period.

The market will experience continuous growth due to a rise in customers who are using personalized medicine and increased requirements for targeted treatment solutions.

Access sample report or view details: https://www.knowledge-sourcing.com/report/pharmacogenomics-testing-market

Key Market Insight & Emerging Trends:

The pharmacogenomics testing market is gaining significant traction as healthcare shifts toward individualized treatment approaches based on genetic profiles. The ability of pharmacogenomics to optimize drug selection and dosage is improving treatment efficacy while minimizing adverse drug reactions.

The development of genomic technologies through next-generation sequencing (NGS) and PCR-based testing methods enables more people to obtain accurate pharmacogenomic testing results. Personalized medicine becomes more widely accepted in clinical environments because healthcare professionals and patients now understand its benefits.

The market expansion receives support from two factors: the integration of pharmacogenomics into standard clinical practice and the growing funding for precision medicine projects. Healthcare systems in the Asia Pacific emerging markets experience increased adoption because their medical facilities are developing better, and patients gain access to sophisticated diagnostic solutions.

• The North American market achieved its maximum share during 2025 because research institutions and genomic testing centers began their operations.

• Reagents and kits made up the majority of the market because these products are required by medical facilities for their ongoing genetic testing processes.

• NGS technology will experience substantial market expansion because it delivers high-throughput performance, and its sequencing expenses continue to decrease.

• The oncology market sector operates as the biggest segment because targeted cancer treatments gain more widespread application.

The pharmacogenomics testing market consists of established companies together with new companies that are working towards enhancing their genomic testing services.

Product Insights: Reagents & Kits Driving Market Demand

The reagents and kits segment held the largest share in 2025 because these consumables serve as fundamental requirements for performing pharmacogenomic assessments. The rising number of genetic tests, together with the growing need for precise medical treatments, leads to ongoing market demand.

Technology Insights: NGS Emerging as a High-Growth Segment

The rapid adoption of next-generation sequencing (NGS) technology results from its capacity to perform accurate tests on multiple genes at once. The technology has gained traction in pharmacogenomics because it helps researchers discover genetic variations that determine how patients react to medications.

Application Insights: Oncology Leading Adoption

The pharmacogenomics testing market is mainly controlled by oncology because genetic testing results help doctors choose effective targeted treatments, which boost patient success rates. The segment experiences growth because of the increasing worldwide cancer cases.

Regional Highlights: North America Leads, Asia Pacific Expands Rapidly

North America retained its dominating position in 2025 because of its advanced medical infrastructure, combined with its strong healthcare regulations and high rates of precision medicine implementation. Additionally, the Asia Pacific region will experience rapid expansion throughout the forecast period because of increasing healthcare spending and rising public knowledge about genomic testing.

Competitive Landscape

As a part of the report, the major players operating in the pharmacogenomics testing market have been covered, such as Roche Diagnostics, Qiagen, Thermo Fisher Scientific, Illumina, Abbott Laboratories, Agilent Technologies, Danaher Corporation, Myriad Genetics, Invitae, and Bio-Rad Laboratories. The companies are working to enhance their market presence through research and development activities and new product partnerships, while new companies enter the market with their affordable, specialized pharmacogenomic testing products.

Market Segmentation

The report segments the pharmacogenomics testing market as follows:

• By Product Type

  • Instruments

  • Reagents & Kits

  • Software & Services

• By Technology

  • Polymerase Chain Reaction (PCR)

  • Next-Generation Sequencing (NGS)

  • Microarrays

  • Mass Spectrometry

• By Application

  • Oncology

  • Neurological Disorders

  • Autoimmune Diseases

  • Metabolic Disorders

  • Cardiovascular Diseases

• By Geography

  • North America

    • USA

    • Canada

    • Mexico

  • South America

    • Brazil

    • Argentina

    • Others

  • Europe

    • United Kingdom

    • Germany

    • France

    • Spain

    • Others

  • Middle East and Africa

    • Saudi Arabia

    • UAE

    • Others

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Indonesia

    • Thailand

    • Others

Companies Profiled:

• Roche Diagnostics

• Thermo Fisher Scientific

• Qiagen

• Illumina

• Abbott Laboratories

• Agilent Technologies

• Danaher Corporation

• Myriad Genetics

• Invitae

• Bio-Rad Laboratories

Explore More Reports:

• Audiological Devices Market

• Life Science Instrumentation Market

• Global Self-Monitoring Blood Glucose (SMBG) Devices Market